ChemotherapyFDA-approvedFirst-line
Paclitaxel
How it works
Interferes with cell division, preventing cancer cells from growing and dividing.
Cancer types
Efficacy
Studies show that paclitaxel can improve survival in patients with ovarian cancer, with a median overall survival of approximately 22 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Gemcitabine and Nab-Paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Gemcitabine and Nab-paclitaxel with TheraBionic P1 for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| New Treatment Approach for Older Adults with Non-Small Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Paclitaxel Oral Solution in Triple Negative Breast Cancer Treatment | Breast Cancer | phase-1 | — | Source → |
| Pembrolizumab and Chemotherapy for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Lurbinectedin with Paclitaxel and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Reducing Corticosteroid Use in Breast Cancer Treatment | Breast Cancer | phase-3 | The omission strategy was associated with improvements in role functioning and reduced worsening of pain, constipation, and nausea/vomiting. | Source → |
| Paclitaxel's Effect on Breast Cancer Cells Varies Across Different Types | Breast Cancer | lab-study | Treatment with PTX for 48 h at concentrations of 12.60 nM in MCF-7, 5.09 nM in BT-474, 16.09 nM in SK-BR-3, and 36.66 nM in MDA-MB-231 cells reduced cell viability and increased apoptosis. | Source → |
| Testing Pembrolizumab and Paclitaxel for Recurring Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing AMP945 with Nab-paclitaxel and Gemcitabine for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Eribulin vs. Taxanes for HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Progression-free survival was 14.0 months with eribulin vs. 13.1 months with docetaxel, and 14.1 months with eribulin vs. 10.8 months with paclitaxel. | Source → |
| Combining Paclitaxel and Eugenol May Improve Lung Cancer Treatment | Lung Cancer | lab-study | The combination treatment with 100 µM Eugenol and 4 µM Paclitaxel synergistically enhanced cytotoxicity compared to individual agents. | Source → |
| New Chemotherapy Combination Shows Promise for Pancreatic Cancer | Pancreatic Cancer | phase-2 | The 6-month progression-free survival rate was 71.0% (95% CI: 57.6%-80.9%). | Source → |
| Pancreatic Cancer Trial Investigates New Combination Therapy | Pancreatic Cancer | phase-2 | — | Source → |
| Testing ONC201 and Paclitaxel in Ovarian Cancer Patients | Ovarian Cancer | phase-2 | — | Source → |
| Combination Therapy Trial for Metastatic Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Pancreatic Cancer Treatment Trial: Surufatinib, Gemcitabine, and Nab-Paclitaxel | Pancreatic Cancer | phase-2 | — | Source → |
| Understanding Resistance to Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Testing IBI343 in Combination with Other Treatments for Advanced Solid Tumors | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Treatments for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing ONT01 with Gemcitabine and Nab-paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a New Combination Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Ovarian Cancer Treatment Trial Evaluates IMNN-001 Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Combination Therapy Shows Promise for Small-Cell Lung Cancer | Lung Cancer | phase-2 | The median progression-free survival was 6.0 months in the ANNAB group and 4.7 months in the NAP group (p = 0.0004). | Source → |
| Paclitaxel Resistance in Lung Cancer: A Key Role for CDKN1A | Lung Cancer | lab-study | — | Source → |
| Testing B013 with Paclitaxel for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| CTDSPL2 linked to paclitaxel resistance in breast cancer cells | Breast Cancer | lab-study | — | Source → |
| Testing DT2216 and Paclitaxel in Platinum-Resistant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for Unresectable Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Chemotherapy's Effect on Gut Microbiome in Breast Cancer Patients | Breast Cancer | animal-study | — | Source → |
| Herbal Formula Enhances Chemotherapy Effectiveness in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Targeted Paclitaxel Delivery for Breast Cancer | Breast Cancer | review | — | Source → |
| Testing Fostamatinib with Chemotherapy in Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Oregovomab with Chemo and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing a New Combination of Medications for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Researchers Identify Lipid Biomarkers for Paclitaxel Side Effect | Breast Cancer | observational | — | Source → |
| New Oral Paclitaxel Shows Similar Efficacy to IV Paclitaxel in Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.0% with DHP107 and 28.6% with IV paclitaxel. | Source → |
| Testing Oral Paclitaxel as First-Line Treatment for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Genetic Causes of Neuropathy in Breast Cancer Patients | Breast Cancer | preclinical | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Testing CFI-402257 with Paclitaxel in Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Paclitaxel Infusion Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel for Breast Cancer: A Bioequivalence Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel Linked to Rare Heart Condition in Breast Cancer Patient | Breast Cancer | observational | — | Source → |
| Link between erythropoietin receptor and ovarian cancer resistance found | Breast Cancer | lab-study | — | Source → |
| Delivering Cancer Medicine with Stem Cell Exosomes | Pancreatic Cancer | lab-study | PTX-loaded exosomes significantly enhanced cytotoxicity compared to free PTX, reducing IC values from 12.48 nM to 7.55 nM in BxPC-3 cells and from 22.44 nM to 19.29 nM in PANC-1 cells. | Source → |
| Vitamin B May Help Reduce Side Effects of Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | A significant reduction in CIPN grade over time was found, with fewer patients progressing to higher grades in the prophylactic versus non-prophylactic group. | Source → |
| ZNF184 Linked to Breast Cancer Resistance to Paclitaxel | Breast Cancer | lab-study | — | Source → |
| TMEPAI Protein Contributes to Paclitaxel Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanosystem Combines Two Cancer Treatments for Better Effect | Melanoma | lab-study | — | Source → |
| Combining Camrelizumab with Gemcitabine and Paclitaxel in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The median overall survival was 14.0 months, and the median progression-free survival was 6.4 months. | Source → |
| New Pathway Linked to Paclitaxel Resistance in Aggressive Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Nanoformulated Phytochemicals Show Promise Against Pancreatic Cancer | Pancreatic Cancer | preclinical | — | Source → |
| Paclitaxel treatment may enhance immune response in aggressive breast cancer | Breast Cancer | lab-study | — | Source → |
| Linoleic Acid May Reduce Effectiveness of Paclitaxel in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Paclitaxel Resistance in Ovarian Cancer: A Potential Target for Treatment | Ovarian Cancer | lab-study | — | Source → |
| Comparing Two Cancer Treatments for Ovarian Cancer | Ovarian Cancer | observational | The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer | Ovarian Cancer | phase-2 | A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel. | Source → |
| Combining paclitaxel and anlotinib for ovarian cancer treatment | Ovarian Cancer | phase-2 | The investigator-evaluated objective response rate was 56.8% in the intention-to-treat population. | Source → |
| Paclitaxel-resistant cancer cells may rely on unstable microtubules | Breast Cancer | lab-study | — | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Paclitaxel Nanoemulsions Show Promise in Treating Breast Cancer | Breast Cancer | lab-study | The nanoemulsion amplified paclitaxel-mediated chromatin condensation and expression of proteins involved in apoptosis, with a 2.5-fold increase in PARP1 cleavage and a 1.7-fold downregulation of BCL2 expression. | Source → |
| Hydrogen Sulfide May Enhance Paclitaxel's Effectiveness Against Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Potential Target for Paclitaxel-Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells Show Resistance to Paclitaxel in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Combining Paclitaxel with Autophagy Inhibitor May Improve Breast Cancer Treatment | Breast Cancer | animal-study | — | Source → |
| Combining Radiation and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-1 | The median overall survival was 22.3 months. | Source → |
| Vitamin E Form δ-Tocotrienol May Enhance Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Understanding Paclitaxel's Effect on Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| New Injectable Gel for Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Tenacissoside G May Help Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Treatment Affects Vision | Pancreatic Cancer | observational | — | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Combining Nadunolimab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The median overall survival was 13.2 months, and the 1-year survival rate was 58%. | Source → |
| Hereditary Breast-Ovarian Cancer Syndrome Responds to Chemotherapy | Ovarian Cancer | observational | The patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| Factors Affecting Chemotherapy-Induced Peripheral Neuropathy in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | — | Source → |
| New Paclitaxel Conjugate Shows Promise in Cancer Treatment | Lung Cancer | lab-study | PTX-RPPR inhibited tumor cell proliferation with an IC ranging from 0.26 to 1.64 μM. | Source → |
| Combining Paclitaxel and Cediranib for Ovarian Cancer Patients at Risk of Bowel Obstruction | Ovarian Cancer | phase-2 | The objective response in patients who received paclitaxel and cediranib was 65.0%. | Source → |
| Paclitaxel Sensitivity in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| New Approach to Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Use Human Fat Cells to Deliver Cancer Drug | Ovarian Cancer | lab-study | The study induced a significant inhibition of tumor growth on a xenograft tumor model. | Source → |
| Paclitaxel Resistance in Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Combining two treatments may slow pancreatic cancer growth | Pancreatic Cancer | animal-study | Sel-GemPac enhanced the survival of treated mice compared to controls (p < .05). | Source → |
| Albumin-Bound Paclitaxel Works Better in Lung and Colorectal Cancers with a Key Protein | Lung Cancer | lab-study | — | Source → |
| RBM15's Role in Ovarian Cancer Resistance to Paclitaxel | Ovarian Cancer | lab-study | — | Source → |
| Combining CAPE and Paclitaxel May Improve Ovarian Cancer Treatment | Ovarian Cancer | lab-study | An increase in the cytotoxic effect was observed in the OV7 line after the simultaneous administration of 10 nM PTX and 100 µM CAPE. | Source → |
| New Cancer Treatment Combination Shows Promise in Pancreatic Cancer | Pancreatic Cancer | phase-1/2 | Among the 21 patients treated at the maximum tolerated dose, 6 (29%) experienced partial response, and median progression-free survival and overall survival times were 11.0 months and 16.2 months, respectively. | Source → |
| Paclitaxel May Induce Cell Death in Ovarian Cancer Cells | Ovarian Cancer | lab-study | — | Source → |
| Nanopaclitaxel Formulations Show Promise in Cancer Treatment | Lung Cancer | phase-3 | Both Nab-paclitaxel and PM-paclitaxel resulted in slightly longer overall survival (HR: 0.93 and 0.94) and progression-free survival (HR: 0.93 and 0.87) when compared with solvent-based paclitaxel. | Source → |
| TIPE2 may help breast cancer cells respond to paclitaxel | Breast Cancer | lab-study | — | Source → |
| Combining Gemcitabine and Nab-Paclitaxel in Ovarian Cancer Treatment | Ovarian Cancer | observational | The median progression-free survival was 9 months (95% CI, 5.7-20.7). | Source → |
| Understanding Resistance to Prostate Cancer Treatments | Prostate Cancer | review | — | Source → |
| Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide for Breast Cancer | Breast Cancer | phase-3 | The hazard ratio of disease-free survival for EP vs EC-P was 0.82 (95% CI, 0.62-1.10). | Source → |
| Smoking's Impact on Breast Cancer Treatment with Bevacizumab | Breast Cancer | observational | Time to treatment failure was significantly longer in the high packs-years group than the low packs-years group (p=0.010, log-rank). | Source → |
| New Chemotherapy Combination Shows Promise for Triple-Negative Breast Cancer | Breast Cancer | phase-2 | After NAC, total pathological complete response was observed in 43.1% of patients. | Source → |
| Modified Tumor Cell Membranes Help Deliver Cancer Treatment | Melanoma | lab-study | — | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The adjusted difference in median overall survival was 3.2 months (95% CI, 1.1-7.4) for FOLFIRINOX compared to gemcitabine plus nab-paclitaxel. | Source → |
| Targeted Delivery of Cancer-Fighting Compounds Improves Treatment Effectiveness | Lung Cancer | lab-study | — | Source → |
| Combining Selinexor and Paclitaxel to Treat Advanced Cancers | Ovarian Cancer | preclinical | Among 24 evaluable patients with ovarian cancer, response rate was 17%, CBR was 58%, and median PFS was 6.8 months (95% CI 3.7, not reached (NR)). | Source → |
| Atezolizumab and Nab-Paclitaxel Combination in Advanced Breast Cancer | Breast Cancer | observational | Median progression-free survival was 3.0 months (95% CI [2.5; 3.5]) and median overall survival was 8.94 months (95% CI [4.35; 13.53]). | Source → |
| New Insights into Pancreatic Cancer Treatment | Pancreatic Cancer | review | — | Source → |
| Tongguanteng Injection May Help Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | TGT combined with PTX showed a synergistic effect and could reverse the IC values of PTX in OC A2780 and A2780/T cells about 23.50 and 6.44 times, respectively. | Source → |
| Targeted Cancer Treatment Shows Promise for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining FKA and PTX nanoparticles may improve ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining two drugs may help fight breast cancer | Breast Cancer | lab-study | The combination of CAM and PAX at a fixed ratio of 1:1 exerted additive interaction in the viability of MCF7 and MDA-MB-231 BC cells. | Source → |
| Gemcitabine plus nab-paclitaxel for elderly pancreatic cancer patients | Pancreatic Cancer | observational | The median overall survival was 10.8 months in the gemcitabine plus nab-paclitaxel group. | Source → |
| Ovarian Cancer Study Finds No Benefit in Adding Pazopanib to Paclitaxel | Ovarian Cancer | phase-2 | There was no difference between treatment arms in 4-month progression-free survival rate (61% with the combination versus 68% with paclitaxel alone). | Source → |
| New Treatment Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Gemcitabine and Nab-Paclitaxel Not Cost-Effective for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | Mean survival was lower for patients in the Gem-Nab than the FOLFIRINOX group (0.98 vs 1.26 life-years; incremental effectiveness = -0.28 life-years [95% confidence interval = -0.47 to -0.13]). | Source → |
| New Combination Therapy Shows Promise for Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Genetic variation linked to side effect in lung cancer treatment | Lung Cancer | lab-study | — | Source → |
| Paclitaxel nanoparticles may improve lung cancer survival | Lung Cancer | phase-3 | — | Source → |
| New Hydrogel Delivers Cancer-Fighting Medicine Directly to Surgical Site | Breast Cancer | animal-study | — | Source → |
| New Cancer Treatment Shows Promise in Ovarian Cancer Patients | Ovarian Cancer | preclinical | The overall objective response rate was 43.2% (95% CI, 28.3 to 59.0): 33.3% (95% CI, 17.3 to 52.8) in patients previously treated with bevacizumab, 64.3% (95% CI, 35.1 to 87.2) in bevacizumab-naive patients, and 62% (95% CI, 31.6 to 86.1) in biomarker-positive patients. | Source → |
| Ovarian Cancer Cells Study Finds New Gene Link | Ovarian Cancer | lab-study | — | Source → |
| Weekly vs. Tri-Weekly Paclitaxel for Ovarian Cancer Treatment | Ovarian Cancer | meta-analysis | There was likely a slight improvement in progression-free survival when paclitaxel was dosed weekly compared to tri-weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98). | Source → |
| Researchers Investigate Chemotherapy for Rare Lung Cancer | Leukemia | phase-2 | The overall response rate was 25.0% and disease control rate was 56.3%. | Source → |
| Aurora Kinase B's Role in Breast Cancer Cells' Resistance to Paclitaxel | Breast Cancer | lab-study | — | Source → |
| KHDRBS3 protein linked to paclitaxel resistance in ovarian cancer | Ovarian Cancer | lab-study | KHDRBS3 knockdown restrained the IC of PTX, cell proliferation, colony formation and glycolysis in SKOV3-R and A2780-R cells in vitro. | Source → |
| Targeted Nanoparticles Improve Chemotherapy Effectiveness | Lung Cancer | animal-study | — | Source → |
| Comparing Neoadjuvant Chemotherapy Regimens for Breast Cancer | Breast Cancer | phase-2 | pCR was seen in 135 (43.1%) patients, with the highest pCR in arm B at 55%. | Source → |
| Ovarian Cancer Survival Rates in Northern India | Ovarian Cancer | observational | The median recurrence-free survival was 30 (95% confidence interval: 24.65-35.38) months. | Source → |
| Paclitaxel Maintenance Therapy May Help Ovarian Cancer Patients | Ovarian Cancer | phase-3 | The 5-year progression-free survival was 28% versus 18% in maintenance and observation arms, respectively. | Source → |
| Comparing Chemotherapy Treatments for Esophageal Cancer | Lung Cancer | phase-2 | The overall response rate in the taxane-based group was higher than the non-taxane-based group, but was not significantly different (p=0.851). | Source → |
| DIAPH1's role in ovarian cancer treatment with paclitaxel | Ovarian Cancer | lab-study | — | Source → |
| LncRNA SNHG7 and Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Lab Study Examines Epigenetic Therapy for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Chemotherapy May Cause Ovarian Cancer Cells to Become Dormant | Ovarian Cancer | lab-study | — | Source → |
| Chemotherapy's Effect on Brain Function Studied | Breast Cancer | observational | — | Source → |
| Testing Chemotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Gemcitabine and nab-paclitaxel in older patients with pancreatic cancer | Pancreatic Cancer | observational | Median progression-free survival was 5.5 months, and overall survival was 12.0 months in the older group. | Source → |
| Ovarian Cancer Treatment Study Finds Key Prognostic Factors | Ovarian Cancer | preclinical | Median progression-free survival was 20.8 months, and median overall survival was 41.1 months. | Source → |
| Rare Pancreatic Cancer Responds to New Chemotherapy Combination | Pancreatic Cancer | phase-2 | — | Source → |
| Nanoparticle Paclitaxel Shows Promise in Treating Breast Cancer | Breast Cancer | meta-analysis | The overall crude frequencies of pathological complete response (pCR) were 18.1, 26.0, and 28.6%. | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median disease control rates were 82.6% for gemcitabine with nab-paclitaxel and 67.9% for modified FOLFIRINOX. | Source → |
| Combination Chemotherapy May Help Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The rate of progressive disease after three cycles of chemotherapy was reduced from 45.6% with gemcitabine to 25.4% with the combination of Nab-paclitaxel and gemcitabine. | Source → |
| MicroRNA May Help Overcome Lung Cancer Resistance to Paclitaxel | Lung Cancer | lab-study | — | Source → |
| Paclitaxel Treatment Efficacy Linked to HER2 Expression in Breast Cancer | Breast Cancer | animal-study | — | Source → |
| Compound May Help Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Atezolizumab Plus Nab-Paclitaxel Therapy for Advanced Breast Cancer: Cost-Effectiveness in Japan | Breast Cancer | phase-3 | The QALYs for AnP treatment were longer than for nP treatment (1.12 vs 0.82 QALYs), but the total cost of AnP treatment was more expensive than that of nP treatment (¥11,070,143 vs ¥2,056,164). | Source → |
| Combining Metformin with Trametinib and Paclitaxel in Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Researchers Investigate New Treatment for Ovarian Cancer | Ovarian Cancer | phase-3 | The CA-125 response rate was 53% in the VB-111 and weekly paclitaxel treated arm. | Source → |
| New Cancer Compounds Show Promise in Lab Experiments | Breast Cancer | lab-study | The most potent compounds show nanomolar antiproliferative potencies against ovarian, breast, and cervix carcinoma cells, similar or even better than paclitaxel. | Source → |
| New Compound May Help Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Paclitaxel Chemotherapy Side Effects in Female Cancer Patients | Breast Cancer | observational | — | Source → |
| Comparing Chemotherapy Options for Pancreatic Cancer | Pancreatic Cancer | review | FOLFIRINOX had significantly better overall survival (OS) and relapse-free survival (RFS)/disease-free survival (DFS)/progression-free survival (PFS) compared to gem-cap and gem-nab/P. | Source → |
| Combining EP0057 and Paclitaxel to Treat Ovarian Cancer | Ovarian Cancer | phase-1/2 | The overall response rate was 31.6% (95% CI: 15.4% to 54.0%) in patients previously treated with bevacizumab. | Source → |
| Low-dose paclitaxel may help some melanoma patients | Melanoma | lab-study | Three patients showed response to therapy (two partial responses and one stable disease) | Source → |
| Chemotherapy Affects Heart Function in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Chemotherapy Side Effect Linked to Higher Costs and Complications | Breast Cancer | observational | — | Source → |
| Cancer Treatment for Breast Cancer Patients Has Challenges | Breast Cancer | observational | — | Source → |
| Link Found Between Biomarkers and Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.